Hillrom today said it has launched two new respiratory health innovations, the Volara System for oscillation and lung expansion therapy and the Synclara Cough System.
“As part of our vision of Advancing Connected Care, we want to make it easy for patients to leave the hospital with the technologies they need to get better faster,” president and CEO John Groetelaars said in a news release. “Our new Volara System is proven to reduce hospital length of stay and time on a ventilator by delivering effective OLE therapy, and the Synclara Cough System, which delivers mechanical insufflation and exsufflation, helps keep upper airways clear. We’re delighted to introduce these practical, accessible innovations to patients and their caregivers.”
The Volara System delivers lung expansion therapy by combining continuous positive expiratory pressure, continuous high frequency oscillation and a nebulizer in one portable, lightweight device. The therapies delivered by the system are suitable for a number of acute and chronic conditions.
Hillrom’s Volara System is versatile to allow patients to receive OLE treatments at home with the same precise settings used in the hospital. It can be used with a mouthpiece, facemask, tracheostomy for in-line on a ventilator.
The company’s Synclara Cough System is a noninvasive therapy that simulates a cough to help remove secretions in patients with compromised peak cough flow, according to the company. It uses mechanical insufflation-exsufflation Technology to clear secretions from the upper airways.
The system is designed with programmability and sensing technology to deliver individualized treatment and specialized patient training, therapy optimization and support.
“For patients with compromised lung function, cough simulation can be a lifesaving therapy,” Groetelaars said. “With Synclara, we’ve developed a cough system that senses how a patient is breathing and automatically adjusts the cough cycle to match the patient’s breathing rhythm, making it possible for caregivers to tailor therapies for specific patient needs.”
Both systems are currently available in the U.S.